Home Cart Sign in  
Chemical Structure| 158966-92-8 Chemical Structure| 158966-92-8

Structure of Montelukast
CAS No.: 158966-92-8

Chemical Structure| 158966-92-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Montelukast is a cysteinyl leukotriene receptor 1 (CysLT1) antagonist widely used for the prevention and treatment of asthma and allergic diseases, with significant clinical applications.

Synonyms: MK0476 free base; MK-476; MK0476

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Montelukast

CAS No. :158966-92-8
Formula : C35H36ClNO3S
M.W : 586.18
SMILES Code : O=C(CC1(CC1)CS[C@H](CCC2=CC=CC=C2C(O)(C)C)C3=CC=CC(/C=C/C4=NC5=CC(Cl)=CC=C5C=C4)=C3)O
Synonyms :
MK0476 free base; MK-476; MK0476
MDL No. :MFCD05662278
InChI Key :UCHDWCPVSPXUMX-TZIWLTJVSA-N
Pubchem ID :5281040

Safety of Montelukast

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Isoform Comparison

Biological Activity

Description
Montelukast (MK0476 free base) is a potent, selective, and orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1). It finds utility in asthma and liver injury research. Moreover, Montelukast exhibits antioxidant properties in intestinal ischemia-reperfusion injury, potentially mitigating cardiac damage. Additionally, it reduces eosinophil infiltration in asthmatic airways and holds promise for COVID-19 research[1][2][3][4].

In Vitro:

Cell Line
Concentration Treated Time Description References
HT-29 cells 50 ng/mL 24 hours Reduced IFNγ-induced PD-L1 expression PMC10265834
Lung ILC2 cells 10^−6 M or 10^−8 M 6 hours To evaluate the effect of montelukast on LTD4-induced IL-4, IL-5, and IL-13 production by ILC2. Results showed that LTD4 significantly induced IL-4, IL-5, and IL-13 production by ILC2, and montelukast pretreatment blocked this effect. PMC3704056
Human CD4+ naïve T cells 0.2 μM, 2 μM, 20 μM 72 hours To study the effect of Montelukast on Th17 cell differentiation. Results showed that Montelukast inhibited Th17 cell differentiation in a dose-dependent manner and suppressed the NF-κB signaling pathway. PMC11008267
HaCaT keratinocytes 10 μM 48 hours To evaluate the effect of Montelukast on M5-induced keratinocyte proliferation. Results showed that Montelukast significantly inhibited keratinocyte proliferation and modulated the NF-κB signaling pathway. PMC11008267
MonoMac6 (MM6) cells 1 μM 1 hour To investigate the inhibitory effect of Montelukast on LTD4-induced expression of cytokines and chemokines. Results showed that Montelukast significantly attenuated the LTD4-induced increases in TNF-α and MIP-1α mRNA and protein levels. PMC5828611
SW480 cells 50 ng/mL 24 hours To investigate the activation of PEPT1 transcription by DAC, results showed DAC activated PEPT1 transcription in a dose-dependent manner. PMC10265834
RKO cells 10 µM 30 minutes To test the effect of SQLE knockdown on 5-FU sensitivity, results showed that SQLE knockdown increased the sensitivity of tumor cells to 5-FU treatment. PMC10265834

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Xenopus oocytes Intragastric 0.2 mg Once daily for three days To evaluate the effect of montelukast on LTD4-induced IL-5 production by ILC2. Results showed that LTD4 significantly increased the percentage of IL-5-producing ILC2, and montelukast pretreatment significantly reduced this effect. PMC3704056
BALB/c mice Hanover Wistar rats Oral 30 mg/kg Once daily, from 1 day before initial infection to Day 6 after infection To evaluate the effects of montelukast on airway hyperresponsiveness and inflammation after RSV infection. Results showed that montelukast administered during primary infection reduced AHR and inflammation and increased IFN-γ production. PMC2937239
Mice CD-1 mice Intraperitoneal injection 1 mg/kg Daily administration from D0 to D6 Montelukast inhibited CYP2C8, and combined treatment with flunarizine further enhanced CNV suppression via suppression of tumor necrosis factor-α expression. PMC9535696
BALB/c mice ICR mice Subcutaneous osmotic pump 1 mg/kg Daily administration for 90 days To evaluate the reversal effect of Montelukast on established airway remodeling. Results showed that Montelukast significantly reduced airway smooth muscle thickening and subepithelial collagen deposition, whereas dexamethasone did not. PMC2662952
BALB/c mice IMQ-induced psoriasis-like model Topical application and intraperitoneal injection 30 mg (cream group), 10 mg/kg (i.p. group) Once daily for 6 consecutive days To evaluate the therapeutic effect of Montelukast on IMQ-induced psoriasis-like lesions. Results showed that Montelukast significantly reduced PASI scores, decreased inflammatory cell infiltration, and inhibited the NF-κB signaling pathway. PMC11008267
Mice CaCl2-induced AAA model, AngII-infused ApoE−/− mice model, PPE-induced AAA model Oral 0.1 mg/kg/d and 1 mg/kg/d Once daily for 21 days To evaluate the preventive and therapeutic effects of Montelukast on AAA development. Results demonstrated that Montelukast significantly reduced aortic dilation, MMP-9 and MIP-1α levels, and showed protective effects in three different AAA models. PMC5828611
Male CD-1 mice Inflammation-induced encephalopathy of prematurity model Intraperitoneal injection 1–30 mg/kg Twice daily from P1 to P4, once on P5, and continued for a further 5 days Montelukast was found to attenuate both peripheral and central inflammation, reducing the expression of pro-inflammatory molecules (IL-1β, IL-6, TNF) in the brain. Inflammation induced a reduction in parvalbumin-positive interneuron density in the cortex, which was normalised with high-dose montelukast. The lowest effective dose, 3 mg/kg, was able to improve anxiety and spatial learning deficits in this model of inflammatory injury, and alterations in cortical mean diffusivity were not present in animals that received this dose of montelukast. PMC9617353
Mice Juvenile mouse brain irradiation injury model Intraperitoneal injection 10 mg/kg Daily for 4 or 14 days To investigate the protective effects of montelukast on radiation-induced injury in the developing brain. Results showed that montelukast reduced cell death during the acute phase after CIR and decreased microglial activation post-irradiation. However, under normal conditions, montelukast reduced hippocampal cell proliferation. PMC6039496

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00299910 Sleep Disordered Breathing PHASE4 UNKNOWN - Pediatric Sleep Center, Soroka... More >> University Medical Center, Beer-Sheva, Israel Less <<
NCT04818723 Nephrotic Syndrome COMPLETED 2020-05-30 Department of Pediatric Nephro... More >>logy, The Children's Hospital and Institute of Child Health, Multan, PPunjab, Pakistan Less <<
NCT01618929 Bronchial Asthma|Food Allergy|... More >>Children Less << PHASE4 COMPLETED 2025-05-16 Cansin Sackesen, Ankara, 06100... More >>, Turkey Less <<
NCT01717625 Premature Birth|Infant, Very L... More >>ow Birth Weight|Bronchopulmonary Dysplasia Less << PHASE2 COMPLETED 2025-10-13 Ajou university medical center... More >>, Suwon, Woncheon-dong, Yeongtong-gu,, 443-721, Korea, Republic of Less <<
NCT01370187 Bronchiolitis|Wheezing|Cough COMPLETED 2025-06-11 Hormozgan University of Medica... More >>l Sciences (HUMS), Bandar Abbas, Hormozgan, 79145-3388, Iran, Islamic Republic of Less <<
NCT02352545 Cough PHASE2 UNKNOWN 2025-10-15 Kewu Huang, China, Beijing, 10... More >>0190, China Less <<
NCT02655562 Coughing PHASE4 SUSPENDED 2025-02-26 Mingming Jiang, Beijing, China
NCT02505113 Portal Vein, Cavernous Transfo... More >>rmation Of Less << UNKNOWN - Department of Radiology, Guang... More >>zhou, Guangdong, 510630, China Less <<
NCT01951898 Asthma PHASE2|PHASE3 UNKNOWN 2025-05-15 Kurume University School of Me... More >>dicine, Kurume, Japan Less <<
NCT01211509 Bronchiolitis Obliterans|Lung ... More >>Transplantation|Graft Rejection Less << PHASE4 COMPLETED 2025-03-15 UZ Gasthuisberg, Leuven, 3000,... More >> Belgium Less <<
NCT01754220 Coughing PHASE4 COMPLETED 2025-12-12 Clinic of Allergy and Asthma, ... More >>University Hospital "Alexandrovska", Sofia, 1431, Bulgaria Less <<
NCT01027806 Obstructive Sleep Apnea PHASE4 TERMINATED 2025-08-14 University of Chicago, Chicago... More >>, Illinois, 60637, United States Less <<
NCT01967498 Chronic Otitis Media With Effu... More >>sion|Conductive Hearing Loss Less << UNKNOWN 2025-05-16 -
NCT00116324 Asthma PHASE3 COMPLETED 2025-12-06 Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States Less <<
NCT00492102 Bronchopulmonary Dysplasia PHASE1 COMPLETED 2025-06-11 Good Samaritan Hospital, Cinci... More >>nnati, Ohio, 45220-2489, United States Less <<
NCT05362474 Diabetic Kidney Disease PHASE3 TERMINATED 2023-06-20 University of Colorado, Aurora... More >>, Colorado, 80045, United States Less <<
NCT02534467 Dermatitis, Atopic PHASE4 COMPLETED 2018-12-04 The Royal Children's Hospital,... More >> Parkville, Victoria, 3052, Australia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.71mL

0.34mL

0.17mL

8.53mL

1.71mL

0.85mL

17.06mL

3.41mL

1.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories